F Sellebjerg
Overview
Explore the profile of F Sellebjerg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
1847
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ammitzboll C, Dyrby T, Bornsen L, Schreiber K, Ratzer R, Romme Christensen J, et al.
Mult Scler Relat Disord
. 2023 Jul;
77:104854.
PMID: 37418931
Background: The potential of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) as biomarkers of disease activity and severity in progressive forms of multiple sclerosis (MS) is unclear....
2.
Lefort M, Sharmin S, Andersen J, Vukusic S, Casey R, Debouverie M, et al.
BMC Med Res Methodol
. 2022 May;
22(1):155.
PMID: 35637426
Background: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment...
3.
Talbot J, Hojsgaard Chow H, Holm Hansen R, von Essen M, Sellebjerg F
J Neuroimmunol
. 2021 Nov;
361:577756.
PMID: 34739914
Dimethyl fumarate is an efficient therapy used widely in patients with relapsing-remitting multiple sclerosis (RRMS). However, lacking effect of treatment has recently been reported in patients with primary progressive MS...
4.
Gustavsen S, Olsson A, Sondergaard H, Andresen S, Sorensen P, Sellebjerg F, et al.
BMC Neurol
. 2021 Aug;
21(1):317.
PMID: 34399707
Background: People with multiple sclerosis (MS) experience a wide range of unpredictable and variable symptoms. The symptomatology of MS has previously been reported in large sample registry studies; however, some...
5.
Olsson A, Gustavsen S, Langkilde A, Hansen T, Sellebjerg F, Bach Sondergaard H, et al.
Mult Scler Relat Disord
. 2021 Jul;
54:103136.
PMID: 34247104
Background: Tight junction proteins contribute to maintenance of epithelial and endothelial barriers such as the intestinal barrier and the blood brain barrier (BBB). Increased permeability of these barriers has been...
6.
Oksbjerg N, Nielsen S, Blinkenberg M, Magyari M, Sellebjerg F
Mult Scler Relat Disord
. 2021 May;
52:102988.
PMID: 33979772
Background: Anti-CD20 antibody therapy may be associated with an increased risk of infections. We therefore investigated risk factors for infection in patients with demyelinating diseases treated with anti-CD20 antibody therapy....
7.
Olsson A, Gustavsen S, Hasselbalch I, Langkilde A, Sellebjerg F, Oturai A, et al.
Mult Scler Relat Disord
. 2020 Sep;
46:102520.
PMID: 32980645
Background: There is a lack of reliable biomarkers predicting disability and disease activity in multiple sclerosis (MS). Recent evidence suggests an involvement of intestinal and pulmonary epithelial barrier function related...
8.
Petersen E, Ammitzboll C, Sondergaard H, Oturai A, Sorensen P, Nilsson A, et al.
J Neuroimmunol
. 2019 Oct;
337:577085.
PMID: 31655423
The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab...
9.
Gustavsen S, Sondergaard H, Andresen S, Magyari M, Sorensen P, Sellebjerg F, et al.
Mult Scler Relat Disord
. 2019 May;
33:5-12.
PMID: 31129415
Background: Use of cannabis to alleviate multiple sclerosis (MS)-related symptoms is increasing. Due to strict regulations, only a minority of MS patients receive cannabis-based prescription drugs. The extent of recreational...
10.
Hasselbalch I, Sondergaard H, Koch-Henriksen N, Olsson A, Ullum H, Sellebjerg F, et al.
Mult Scler J Exp Transl Clin
. 2018 Dec;
4(4):2055217318813183.
PMID: 30515298
Background: Subtypes of white blood cell counts are known biomarkers of systemic inflammation and a high neutrophil-to-lymphocyte ratio (NLR) has been associated with several autoimmune diseases. Few studies have investigated...